Kim Chang Woo, Cho Min Soo, Baek Se Jin, Hur Hyuk, Min Byung Soh, Kang Jeonghyun, Baik Seung Hyuk, Lee Kang Young, Kim Nam Kyu
Division of Colon and Rectal Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Ann Surg Oncol. 2015 Mar;22(3):924-30. doi: 10.1245/s10434-014-4039-1. Epub 2014 Sep 9.
The aim of this study was to investigate oncologic outcomes, as well as perioperative and pathologic outcomes, of single-incision laparoscopic anterior resection (SILAR) compared with conventional laparoscopic anterior resection (CLAR) for sigmoid colon cancer using propensity-score matching analysis.
From July 2009 through April 2012, a total of 407 patients underwent laparoscopic anterior resection for sigmoid colon cancer. Data on short- and long-term outcomes were collected prospectively and reviewed. Propensity-score matching was applied at a ratio of 1:2 comparing the SILAR (n = 60) and CLAR (n = 120) groups.
There was no difference in operation time, estimated blood loss, time to soft diet, and length of hospital stay; however, the SILAR group showed less pain on postoperative day 2 (mean 2.6 vs. 3.6; p = 0.000) and shorter length of incision (3.3 vs. 7.7 cm; p = 0.000) compared with the CLAR group. Morbidity, mortality, and pathologic outcomes were similar in both groups. The 3-year overall survival rates were 94.5 versus 97.1% (p = 0.223), and disease-free survival rates were 89.5 versus 87.4% (p = 0.751) in the SILAR and CLAR groups, respectively.
The long-term oncologic outcomes, as well as short-term outcomes, of SILAR are comparable with those of CLAR. Although SILAR might have some technical difficulties, it appears to be a safe and feasible option, with better cosmetic results.
本研究旨在通过倾向评分匹配分析,比较单切口腹腔镜前切除术(SILAR)与传统腹腔镜前切除术(CLAR)治疗乙状结肠癌的肿瘤学结局、围手术期结局和病理结局。
2009年7月至2012年4月,共有407例患者接受了乙状结肠癌的腹腔镜前切除术。前瞻性收集并回顾了短期和长期结局的数据。以1:2的比例应用倾向评分匹配,比较SILAR组(n = 60)和CLAR组(n = 120)。
手术时间、估计失血量、恢复软食时间和住院时间无差异;然而,与CLAR组相比,SILAR组术后第2天疼痛较轻(平均2.6 vs. 3.6;p = 0.000),切口长度较短(3.3 vs. 7.7 cm;p = 0.000)。两组的发病率、死亡率和病理结局相似。SILAR组和CLAR组的3年总生存率分别为94.5%和97.1%(p = 0.223),无病生存率分别为89.5%和87.4%(p = 0.751)。
SILAR的长期肿瘤学结局以及短期结局与CLAR相当。尽管SILAR可能存在一些技术困难,但它似乎是一种安全可行的选择,具有更好的美容效果。